M2RT34 logo

Mirati Therapeutics BOVESPA:M2RT34 Stock Report

Last Price

R$19.46

Market Cap

R$20.5b

7D

0.6%

1Y

29.0%

Updated

23 Jan, 2024

Data

Company Financials +

Mirati Therapeutics, Inc.

BOVESPA:M2RT34 Stock Report

Market Cap: R$20.5b

M2RT34 Stock Overview

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. More details

M2RT34 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Mirati Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Mirati Therapeutics
Historical stock prices
Current Share PriceUS$19.46
52 Week HighUS$21.64
52 Week LowUS$9.00
Beta0.77
1 Month Change1.35%
3 Month Change4.96%
1 Year Change28.96%
3 Year Changen/a
5 Year Changen/a
Change since IPO-54.84%

Recent News & Updates

Recent updates

Shareholder Returns

M2RT34BR BiotechsBR Market
7D0.6%-2.4%-0.8%
1Y29.0%-2.0%-13.7%

Return vs Industry: M2RT34 exceeded the BR Biotechs industry which returned -1.1% over the past year.

Return vs Market: M2RT34 exceeded the BR Market which returned 9.3% over the past year.

Price Volatility

Is M2RT34's price volatile compared to industry and market?
M2RT34 volatility
M2RT34 Average Weekly Movement1.7%
Biotechs Industry Average Movement9.2%
Market Average Movement5.0%
10% most volatile stocks in BR Market9.6%
10% least volatile stocks in BR Market2.9%

Stable Share Price: M2RT34 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine M2RT34's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995587Chuck Baumwww.mirati.com

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation.

Mirati Therapeutics, Inc. Fundamentals Summary

How do Mirati Therapeutics's earnings and revenue compare to its market cap?
M2RT34 fundamental statistics
Market capR$20.53b
Earnings (TTM)-R$3.62b
Revenue (TTM)R$190.40m

107.8x

P/S Ratio

-5.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
M2RT34 income statement (TTM)
RevenueUS$38.19m
Cost of RevenueUS$510.48m
Gross Profit-US$472.29m
Other ExpensesUS$253.59m
Earnings-US$725.88m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-10.35
Gross Margin-1,236.66%
Net Profit Margin-1,900.65%
Debt/Equity Ratio0%

How did M2RT34 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/23 19:52
End of Day Share Price 2024/01/22 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mirati Therapeutics, Inc. is covered by 31 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
George FarmerBMO Capital Markets Equity Research
Jason Matthew GerberryBofA Global Research